Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women
- PMID: 31264912
- PMCID: PMC6797070
- DOI: 10.1089/jwh.2018.7340
Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women
Abstract
Background: Despite a reduction in the prevalence of vaccine-preventable types of human papillomavirus (HPV), attributed to increased HPV vaccine uptake, HPV continues to be a major cause of cancer in the United States. Methods: We assessed factors associated with self-reported HPV vaccine uptake, HPV vaccination effectiveness, using DNA testing to assess HPV types 16 and/or 18 (HPV 16/18) positivity, and patterns of HPV vaccination in 375 women aged 21-29 years who were eligible to receive catch-up vaccination, using baseline data collected from March 2012 to December 2014 from a randomized controlled trial evaluating a novel approach to cervical cancer screening. Results: More than half (n = 228, 60.8%) of participants reported receipt of at least one HPV vaccine dose and 16 (4.3%) tested positive for HPV 16/18 at baseline. College-educated participants were four times more likely to have been vaccinated than those reporting high school education or less. 56.5% of HPV-vaccinated participants reported first dose after age 18 and 68.4% after first vaginal intercourse. Women vaccinated after age 18 and women vaccinated after first vaginal intercourse were somewhat more likely to be infected with HPV 16/18 infection compared with women vaccinated earlier, but these associations did not reach statistical significance. Conclusions: HPV vaccination is common among college-educated women in the catch-up population but less common among those without college education. Contrary to current guidelines, catch-up females frequently obtain HPV vaccination after age 18 and first vaginal intercourse. Women without a college education represent an ideal population for targeted HPV vaccination efforts that emphasize vaccination before sexual debut.
Trial registration: ClinicalTrials.gov NCT01550783.
Keywords: HPV; catch-up population; correlates; human papillomavirus; vaccination.
Conflict of interest statement
There are no competing financial interests to report.
Figures
Similar articles
-
Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.PLoS One. 2016 Aug 2;11(8):e0160099. doi: 10.1371/journal.pone.0160099. eCollection 2016. PLoS One. 2016. PMID: 27482705 Free PMC article.
-
Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.Hum Vaccin Immunother. 2018 Jan 2;14(1):118-123. doi: 10.1080/21645515.2017.1385688. Epub 2017 Dec 13. Hum Vaccin Immunother. 2018. PMID: 29049007 Free PMC article.
-
Human papillomavirus vaccination and cervical cytology in young minority women.Sex Transm Dis. 2014 Aug;41(8):511-4. doi: 10.1097/OLQ.0000000000000162. Sex Transm Dis. 2014. PMID: 25013981
-
Indications and efficacy of the human papillomavirus vaccine.Curr Treat Options Oncol. 2007 Dec;8(6):393-401. doi: 10.1007/s11864-007-0050-0. Curr Treat Options Oncol. 2007. PMID: 18172770 Review.
-
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.Expert Rev Vaccines. 2016;15(3):367-87. doi: 10.1586/14760584.2016.1124763. Expert Rev Vaccines. 2016. PMID: 26902666 Review.
Cited by
-
Comparative Molecular Docking of Apigenin and Luteolin versus Conventional Ligands for TP-53, pRb, APOBEC3H, and HPV-16 E6: Potential Clinical Applications in Preventing Gynecological Malignancies.Curr Issues Mol Biol. 2024 Oct 3;46(10):11136-11155. doi: 10.3390/cimb46100661. Curr Issues Mol Biol. 2024. PMID: 39451541 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Human papillomavirus (HPV)—Know the facts. Atlanta: U.S. Department of Health and Human Services, 2015. Available at: www.cdc.gov/std/hpv stdfact-hpv.htm Accessed April9, 2016
-
- Markowitz L, Hariri S, Lin C, et al. . Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013;208:385–393 - PubMed
-
- Centers for Disease Control and Prevention. HPV vaccine recommendations. Atlanta, GA: U.S. Department of Health and Human Services, 2016. Available at: www.cdc.gov/vaccines/vpd/hpv/hcp recommendations.html Accessed April1, 2017
-
- Donken R, Schurink-Van't Klooster TM, Schepp RM, et al. . Immune responses after 2 versus 3 doses of HPV vaccination up to 4½ years after vaccination: An observational study among Dutch routinely vaccinated girls. J Infect Dis 2017;215:359–367 - PubMed
-
- Dobson SR, McNeil S, Dionne M, et al. . Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA 2013;309:1793–1802 - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical